Influence of the combination of SGLT2 inhibitors and GLP-1 receptor agonists on eGFR decline in type 2 diabetes: post-hoc analysis of RECAP study.

combination therapy diabetic kidney disease glucagon-like peptide 1 receptor agonists preceding drug renal outcome sodium-glucose cotransporter 2 inhibitors

Journal

Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923

Informations de publication

Date de publication:
2024
Historique:
received: 20 12 2023
accepted: 11 03 2024
medline: 11 4 2024
pubmed: 11 4 2024
entrez: 11 4 2024
Statut: epublish

Résumé

Accumulating evidence has demonstrated that both SGLT2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP1Ra) have protective effects in patients with diabetic kidney disease. Combination therapy with SGLT2i and GLP1Ra is commonly used in patients with type 2 diabetes (T2D). We previously reported that in combination therapy of SGLT2i and GLP1Ra, the effect on the renal composite outcome did not differ according to the preceding drug. However, it remains unclear how the initiation of combination therapy is associated with the renal function depending on the preceding drug. In this

Identifiants

DOI: 10.3389/fphar.2024.1358573 PMID: 38601470 PMC: PMC11005912
pubmed: 38601470
doi: 10.3389/fphar.2024.1358573
pii: 1358573
pmc: PMC11005912
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1358573

Informations de copyright

Copyright © 2024 Muta, Kobayashi, Toyoda, Tone, Suzuki, Tsuriya, Machimura, Shimura, Takeda, Yokomizo, Takeshita, Chin, Kanasaki, Tamura, Miyauchi, Saburi, Morita, Yomota, Kimura, Hatori, Nakajima, Ito, Tsukamoto, Murata, Matsushita, Furuki, Hashimoto, Umezono, Takashi and Kawanami.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Yoshimi Muta (Y)

Department of Endocrinology and Diabetes, Fukuoka University School of Medicine, Fukuoka, Japan.

Kazuo Kobayashi (K)

Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Kanagawa, Japan.

Masao Toyoda (M)

Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine, Kanagawa, Japan.

Atsuhito Tone (A)

Department of Internal Medicine, Diabetes Center, Okayama Saiseikai General Hospital, Okayama, Japan.

Daisuke Suzuki (D)

Suzuki Diabetes Clinic, Kanagawa, Japan.

Daisuke Tsuriya (D)

Division of Endocrinology and Metabolism, 2nd Department of Internal Medicine, Hamamatsu University School of Medicine, Shizuoka, Japan.

Hideo Machimura (H)

Machimura Internal Medicine Clinic, Kanagawa, Japan.

Hidetoshi Shimura (H)

Shimura Clinic, Kanagawa, Japan.

Hiroshi Takeda (H)

Takeda Clinic, Kanagawa, Japan.

Hisashi Yokomizo (H)

Department of Endocrinology and Diabetes, Fukuoka University School of Medicine, Fukuoka, Japan.

Kei Takeshita (K)

Division of Endocrinology and Metabolism, 2nd Department of Internal Medicine, Hamamatsu University School of Medicine, Shizuoka, Japan.

Keiichi Chin (K)

Hakuai Clinic, Kanagawa, Japan.

Keizo Kanasaki (K)

Department of Internal Medicine 1, Endocrinology and Metabolism, Shimane University Faculty of Medicine, Shimane, Japan.

Kouichi Tamura (K)

Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Kanagawa, Japan.

Masaaki Miyauchi (M)

Miyauchi Diabetes Clinic, Kanagawa, Japan.

Masuo Saburi (M)

Department of Diabetology, Endocrinology and Metabolism, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan.

Miwa Morita (M)

Department of Internal Medicine 1, Endocrinology and Metabolism, Shimane University Faculty of Medicine, Shimane, Japan.

Miwako Yomota (M)

Department of Internal Medicine 1, Endocrinology and Metabolism, Shimane University Faculty of Medicine, Shimane, Japan.

Moritsugu Kimura (M)

Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine, Kanagawa, Japan.

Nobuo Hatori (N)

Kobayashi Hospital, Kanagawa, Japan.

Shinichi Nakajima (S)

Sagami Junkanki Clinic, Kanagawa, Japan.

Shun Ito (S)

Department of Internal Medicine, Sagamihara Red Cross Hospital, Kanagawa, Japan.

Shunichiro Tsukamoto (S)

Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Kanagawa, Japan.

Takashi Murata (T)

Department of Clinical Nutrition, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Diabetes Center, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.

Takaya Matsushita (T)

Department of Diabetology, Endocrinology and Metabolism, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan.

Takayuki Furuki (T)

Hadano Station South Gate Clinic, Kanagawa, Japan.

Takuya Hashimoto (T)

Division of Endocrinology and Metabolism, 2nd Department of Internal Medicine, Hamamatsu University School of Medicine, Shizuoka, Japan.

Tomoya Umezono (T)

Umezono Internal Medicine Clinic, Kanagawa, Japan.

Yuichi Takashi (Y)

Department of Endocrinology and Diabetes, Fukuoka University School of Medicine, Fukuoka, Japan.

Daiji Kawanami (D)

Department of Endocrinology and Diabetes, Fukuoka University School of Medicine, Fukuoka, Japan.

Classifications MeSH